This article is more than 5 years old. Information may no longer be current.

STAAR submits Toric ICL for U.S. marketing approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — STAAR Surgical has submitted a Pre-Marketing Approval supplement to U.S. regulators for its Visian TICL, a toric implantable collamer lens, the company announced in a press release.

The TICL is designed to treat both myopia and astigmatism, STAAR said. The supplemental filing “supports an indication for use in adults 21 to 45 years of age for the correction of myopia ranging from –3 D to –20 D with astigmatism of 1 D to 4 D,” the release said. The application serves as a supplement to the PMA for its Myopic Visian ICL, the company said.

“If approved, the TICL will be the only phakic implantable lens product available in the U.S. to treat myopia and astigmatism,” David Bailey, president and chief executive officer of STAAR Surgical, said in the press release.